Prognostic value of morphologic and clinical parameters in pT2 - pT3 prostate cancer

Almeida, Jose C.; Menezes, Raissa P.; Kuckelhaus, Selma As; Bocca, Anamélia Lorenzetti; Figueiredo, Florêncio

doi:10.1590/s1677-55382007000500007

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty‐three of these studies correlated the presence of neuroendocrine staining to patient outcomes such as biochemical recurrence, clinical progression, overall survival and prostate cancer‐specific survival. The characteristics of the included studies are summarized in Table 1 [19–80] and Table S2.…”

Section: Resultsmentioning

confidence: 99%

Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

To perform a systematic review and meta-analysis of the literature to understand the variation in the reporting of neuroendocrine staining and determine the influence of reporting neuroendocrine staining at diagnosis on patient outcomes. MethodsMedical databases were searched to identify studies in which adenocarcinoma specimens were stained with any of the following four neuroendocrine markers: chromogranin A (CgA), neuron-specific enolase (NSE), synaptophysin and CD56. The prevalence of neuroendocrine staining and correlation of the prevalence of neuroendocrine staining to patient outcomes were analysed using a random-effects model. All statistical tests were two-sided. ResultsSixty-two studies spanning 7616 patients were analysed. The pooled prevalence for the most common marker, CgA (41%), was similar to that of NSE (39%) and higher than that of synaptophysin (31%). The prevalence of CgA staining was significantly influenced by reporting criteria, where objective thresholds reduced the variation in prevalence to 26%. No correlation was found between CgA prevalence and tumour grade. Patients positive for CgA staining using objective criteria had more rapid biochemical progression (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.49 to 2.65) and poorer prostate cancer-specific survival (HR 7.03, 95% CI 2.55 to 19.39) compared to negative patients, even among those with low-risk cancers. ConclusionDiscrepancies in the reported prevalence of neuroendocrine cells in adenocarcinoma are driven by the inconsistent scoring criteria. This study unequivocally demonstrates that when neuroendocrine cell staining is assessed with objective criteria it identifies patients with poor clinical outcomes. Future studies are needed to determine the exact quantifiable thresholds for use in reporting neuroendocrine cell staining to identify patients at higher risk of progression.

show abstract

Section: Resultsmentioning

confidence: 99%

Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

Análise de complicações em pacientes portadores de câncer de próstata metastático submetidos à orquiectomia bilateral

Silva

Neto

Lima

2010

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

show abstract

Ki67 is a promising molecular target in the diagnosis of cancer (Review)

Jiang

Chen

et al. 2014

Molecular Medicine Reports

587

445

View full text Add to dashboard Cite

The expression of Ki67 is strongly associated with tumor cell proliferation and growth, and is widely used in routine pathological investigation as a proliferation marker. The nuclear protein Ki67 (pKi67) is an established prognostic and predictive indicator for the assessment of biopsies from patients with cancer. Clinically, pKi67 has been shown to correlate with metastasis and the clinical stage of tumors. In addition, it has been shown that Ki67 expression is significantly higher malignant tissues with poorly differentiated tumor cells, as compared with normal tissue. According to its predictive role, pKi67 expression identifies subpopulations of patients who are more likely to respond to a given therapy. The Ki67 labeling index is an independent prognostic factor for survival rate, which includes all stages and grade categories. There is a correlation between the ratio of Ki67‑positive malignant cells and patient survival. It has been shown that blocking of Ki67 either by microinjection of antibodies or through the use of antisense oligonucleotides leads to the arrest of cell proliferation. Specifically, antisense oligonucleotides and antibodies against pKi67 have been shown to inhibit the progression of the cell cycle. The Ki67 protein is well characterized at the molecular level and is extensively used as a prognostic and predictive marker for cancer diagnosis and treatment. Increasing evidence indicates that Ki67 may be an effective target in cancer therapy. It therefore merits further development, including testing in more sophisticated in vitro and appropriate in vivo models. This review provides an overview of recent advances in this field.

show abstract

Prognostic value of morphologic and clinical parameters in pT2 - pT3 prostate cancer

Cited by 3 publications

References 27 publications

Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysis

Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysis

Análise de complicações em pacientes portadores de câncer de próstata metastático submetidos à orquiectomia bilateral

Ki67 is a promising molecular target in the diagnosis of cancer (Review)

Contact Info

Product

Resources

About